Glucagon-Like Peptide 1 Market Research Report 2025: Preference for Injectable Therapies, Clinical Efficacy, Safety Demand, & Advancements in Diabetes Research Fueling Growth - Forecast to 2034

The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

Dublin, April 04, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide 1 Market Report 2025" report has been added to ResearchAndMarkets.com's offering.

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%.

The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research.

The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.

The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.

Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.

Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.

North America was the largest region in the glucagon-such as peptide 1 market in 2024. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Glucagon-like Peptide 1 Market Competitive Landscape

• Novo Nordisk AS Overview, Products and Services, Strategy and Financial Analysis
• Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
• Eli Lilly and Co Overview, Products and Services, Strategy and Financial Analysis
• AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
• Pfizer Overview, Products and Services, Strategy and Financial Analysis

Other Innovative Companies

• Boehringer Ingelheim International GmbH
• F Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Baxter International
• Hikma Pharmaceuticals plc
• Zealand Pharma a/S
• Intarcia Therapeutics Inc.
• GlaxoSmithKline plc
• Jiangsu Hansoh Pharmaceutical Group Co Ltd
• Shanghai Benemae Pharmaceutical Corporation
• Adocia
• Biocon
• Hanmi Pharmaceutical Co Ltd
• Ligand Pharmaceuticals Incorporated
• Advinus Therapeutics Ltd

Key Attributes:

Key Topics Covered:

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends and Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market

5. Global Glucagon-like Peptide 1 Growth Analysis and Strategic Analysis Framework
5.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Glucagon-like Peptide 1 Market Growth Rate Analysis
5.4. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Glucagon-like Peptide 1 Total Addressable Market (TAM)

6. Glucagon-like Peptide 1 Market Segmentation
6.1. Global Glucagon-like Peptide 1 Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Trulicity
• Ozempic
• Victoza
• Rybelsus
• Other Types

6.2. Global Glucagon-like Peptide 1 Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Oral
• Parenteral
• Other Routes

6.3. Global Glucagon-like Peptide 1 Market, Segmentation by End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Hospitals
• Specialty Clinics
• Other End Users

6.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation of Trulicity, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Injection (pre-filled pen)
• Dosage forms (0.75 mg, 1.5 mg, etc.)

6.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation of Ozempic, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Injection (pre-filled pen)
• Dosage forms (0.5 mg, 1 mg, etc.)

6.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation of Victoza, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Injection (pre-filled pen)
• Dosage forms (1.2 mg, 1.8 mg, etc.)

6.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation of Rybelsus, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Oral tablet (3 mg, 7 mg, 14 mg)

6.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation of Other Types, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Experimental formulations
• Combination products with other medications
• Alternative delivery systems

7. Glucagon-like Peptide 1 Market Regional and Country Analysis
7.1. Global Glucagon-like Peptide 1 Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glucagon-like Peptide 1 Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/o0iw68

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900